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Abstract
Dystonias are a clinically and etiologically diverse group of  disorders. Numerous genes have now been associated with different dystonia syndromes, and multiple 
strategies have been proposed for how these genes should be lumped and split into meaningful categories. The traditional approach has been based on the Human 
Genome Organization’s plan for naming genetic loci for all disorders. For dystonia this involves a DYT prefix followed by a number (e.g., DYT1, DYT2, DYT3, etc.). 
A more recently proposed approach involves assigning multiple prefixes according to the main elements of  the phenotype (e.g., DYT, PARK, CHOR, TREM, etc.) 
followed by the name of  the responsible gene. This article describes these nomenclature systems and summarizes some of  their limitations. We focus on dystonia as 
an example, although the concepts may be applied to all movement disorders.
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Brief history of gene nomenclature
Historically, most disease-associated genes were discovered by a process 
known as “linkage analysis.” In brief, large families with multiple individ-
uals affected by a specific disorder were collected, and genetic “markers” 
with known locations spread across all chromosomes were examined for 
family members with and without the disorder. Then, large stretches of  
DNA were sequenced in the chromosomal locations closest to the markers 
that correlated best with the disease phenotype. Having multiple large and 
unrelated families greatly aided this process by increasing the statistical 
power to detect correlations between the disease phenotype and the 
genetic marker. Therefore, identifying multiple unrelated families with the 
same condition was historically essential for the identification of  novel 
disease genes.
To aid the process of  identifying families with similar disorders, the 
Human Genome Organization (HUGO) developed a convention for 
acknowledging potential new genes for families in which linkage studies 
pointed to a specific chromosomal location or “locus.” HUGO intended 
that the locus name should be dropped after the gene was discovered 
because knowing the gene is more important than linkage-based  statistical 
estimates of  its location in the genome. Therefore, the original intention 
of  the HUGO locus nomenclature system was to provide a temporary 
label to aid in the identification of  families for linkage analyses.
The HUGO convention was applied for naming loci for candidate 
genes to all human disorders. Movement disorders were grouped accord-
ing to the main aspects of  the clinical phenotype and given a specific 
prefix such as Parkinson’s disease (PARK), spinocerebellar ataxia (SCA), 
hereditary spastic paraplegia (HSP), or dystonia (DYT). When linkage 
studies for a new family pointed to a novel locus different from previously 
identified loci, the prefix was appended with a distinct number (e.g., 
DYT1, DYT2, DYT3, etc.). In this way, multiple unrelated families that 
might share defects in the same gene could be identified and analyzed 
together to improve the chances of  finding the relevant gene.
Prefix assignments were never generated for certain disorders where link-
age studies had not yet identified meaningful targets, including tremor, 
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myoclonus, paroxysmal dyskinesias, and others. This simple nomencla-
ture system has been in use for many years, but it has also led to numer-
ous problems.1 The problems are illustrated here using dystonia as an 
example, although similar problems have been described for other move-
ment disorders.
The DYT prefix is misleading
The DYT prefix was intended for disorders where dystonia is an 
important aspect of  the phenotype. This is not always the case. For 
example, the myoclonus–dystonia syndrome was assigned to the DYT11 
locus, and at least one causative gene has been identified (SGCE). 
However, the most consistent feature of  this disorder is myoclonus, not 
dystonia.2,3 Many patients with this disorder also have dystonia, and dys-
tonia may sometimes be severe. However, dystonia is often quite subtle, 
with a slight tilting of  the head, or slightly scalloped posture of  a hand. 
Sometimes there is myoclonus without any dystonia, and the disorder is 
then called essential myoclonus. Similarly, the paroxysmal dyskinesias 
were assigned to DYT8 (MR-1), DYT10 or DYT19 (PRRT2), and DYT9 
or DYT18 (SLC2A1). However, in these disorders, the movement disor-
der is quite varied and reflects various combinations of  dystonia, cho-
rea, ataxia, and sometimes other abnormalities.4 Dystonia is not always 
a prominent feature of  these conditions. In other words, lists of  genes 
with the DYT label misleadingly imply that they all designate disorders 
where dystonia is an important aspect of  the phenotype.
In other cases, the DYT prefix was applied appropriately, but subse-
quent identification of  the gene led to recognition of  alternative pheno-
types where dystonia was a minor component or even lacking. For 
example, DYT9 and DYT18 were assigned to paroxysmal exertional 
dyskinesia, where the most prominent movement abnormality is dystonic 
posturing following exercise.5 Identification of  the associated gene 
(SLC2A1) led to the appreciation that the same gene was already linked 
with several other phenotypes, including infantile encephalopathy with 
seizures and ataxia, several different types of  epilepsy, and hemiplegic 
migraine.6 In fact, paroxysmal exertional dyskinesia is a relatively 
 uncommon phenotype for pathological genetic variants in SLC2A1. 
Similarly, DYT12 was assigned to the syndrome of  rapid-onset 
 dystonia-parkinsonism, where dystonia is a frequent and prominent 
problem.7 However, the responsible gene (ATP1A3) was again linked with 
other phenotypes, including alternating hemiplegia of  childhood and 
CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy, 
and sensorineural hearing loss).8 In these other disorders, dystonia may 
be minor or absent. In other words, discovery of  a gene associated with 
some DYT loci led to the realization that dystonia was a relatively minor 
phenotype of  a more complex group of  clinical syndromes.
In addition to having several DYT labels assigned to disorders 
where dystonia is sometimes minor, the converse is also true; there 
are multiple disorders where dystonia is a consistent or major aspect 
of  the clinical phenotype, yet they lack DYT labels. In some cases, the 
reason is that the gene was identified before the DYT naming conven-
tion was established. For example, dystonia is universal in classic 
Lesch–Nyhan disease,9 and may be the presenting or main problem in 
the Lesch–Nyhan variants.10 The responsible gene, HPRT1, was found 
in 1985 before the DYT convention started. Similarly, dystonia occurs in 
the majority of  individuals with neurological Wilson’s disease (ATP7B).11 
In some cases, dystonia is the presenting problem, or the most disabling 
problem. Despite the prevalence and severity of  dystonia in Lesch–
Nyhan disease and Wilson’s disease, neither has been assigned a DYT 
label. In fact, there are more than 100 disorders without DYT labels 
where dystonia may be an important feature of  the phenotype.12
More recently, several new genes have been discovered where dysto-
nia is a prominent feature of  the phenotype. An example involves 
defects in manganese transporters linked to the SLC39A14 or SLC30A10 
genes, where dystonia is a consistent and prominent problem.13–15 In 
both cases, a DYT prefix was not assigned because dystonia was only 
one feature of  a more complex phenotype, and assigning a DYT prefix 
neglected other important aspects of  the phenotype. The methods for 
gene discovery in these more recent studies were less dependent on tra-
ditional linkage methods; therefore, there was no value in assigning a 
DYT locus label. Nowadays, more genes are being found using methods 
where linkage analysis plays a minor role.
Clinicians need access to complete and accurate lists of  dystonia 
genes for diagnostic purposes. Basic scientists need access to complete 
and accurate lists to elucidate biological pathways. The traditional lists 
of  disorders with the DYT prefix misleadingly imply that dystonia is a 
consistent or major aspect of  the disorders listed. These lists also 
are misleadingly incomplete because they neglect a large number of  
disorders where dystonia is relevant.
The numbering convention has become inconsistent
In addition to the DYT prefix being misleading, the numbering sys-
tem has become confusing because of  inconsistent use and multiple 
errors. If  a locus aims to guide investigations for a unique dystonia gene, 
then there should be a one-to-one correspondence between one locus 
name and one gene. This is not the case. DYT5 (dopa-responsive dysto-
nia) includes at least two genes (GCH1 and TH).16 Genetic variants in 
SPR were later found to cause the dopa-responsive dystonia phenotype 
by a candidate gene approach, and not by linkage analysis; therefore, a 
locus was never assigned. However, some investigators have begun to 
include SPR under the DYT5 umbrella because of  a shared pheno-
type.17,18 Therefore, DYT5 has become synonymous with the dopa- 
responsive dystonia phenotype, not a label for a unique genetic locus.
The DYT2 label has evolved in a similarly confusing way. This label 
was originally reserved for a family with autosomal recessive dystonia. 
Multiple unrelated families with autosomal recessive dystonia were later 
described as DYT2.19–21 Occasionally, the term “DYT2-like” was used 
when the dystonic phenotype did not precisely match the original  family. 
The HPCA gene was later identified for one of  these families,22 and has 
now taken the DYT2 label. However, no linkage studies were conducted 
for any of  these families, and therefore it is impossible to know if  any 
shared the same locus or gene. Like DYT5 for dopa-responsive dysto-
nia, the DYT2 label has transformed from a locus into a phenotype, 
which is caused by multiple different genes.
Just as some DYT labels may have multiple genes, several genes have 
multiple DYT labels. For example, the SLC2A1 gene accounts for both 
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DYT9 and DYT18 and the PRRT2 gene accounts for DYT10 and DYT19. 
These discrepancies were caused by errors in the original assignments of  a 
DYT number to what was thought to be a unique locus for a unique gene.
In other cases, DYT loci were erroneously assigned because the orig-
inal linkage analysis was wrong. For example, classical linkage studies 
designated DYT14 as a novel locus for dopa-responsive dystonia unre-
lated to the previously designated locus (DYT5) for dopa-responsive dys-
tonia caused by pathological genetic variants in GCH1. However, the 
gene responsible for DYT14 proved to be the same gene (GCH1) because 
incorrect phenotypic assessments led to a misleading linkage analysis 
result.23 The existence of  a dystonia gene for cervical dystonia at the 
DYT7 locus in one large family has similarly been questioned because 
of  uncertainties in assigning the phenotypic status for affected versus 
unaffected family members.24 These errors emphasize that loci defined 
by linkage studies are statistical estimates of  the locations of  presumed 
genes that are based on phenotypes that may be mild or may evolve with 
age; therefore, there will always be some chance that they are wrong.
Finally, there is at least one example where the DYT label did not 
follow the standard naming convention. The term “DYT-CA” was 
coined to describe a phenotype of  cervical dystonia combined with pro-
gressive cerebellar ataxia.25 This label seems quite sensible because of  
the combination of  dystonia and ataxia, but its position in lists relative 
to other DYT loci causes confusion, and this disorder is therefore often 
omitted from gene lists that follow the HUGO tradition.
Recently proposed nomenclature plan
To address the many problems with HUGO’s original nomenclature 
system, a new system was proposed by a task force for genetic nomencla-
ture in the Movement Disorders Society (MDS).26 The new proposal 
called for several major changes: (1) Multiple prefixes would be com-
bined to better recognize the phenotype, (2) new phenotype prefixes 
would be established where they were previously lacking, (3) the num-
bering system would be replaced by the actual gene name, (4) all disor-
ders would be given a label under the new system, including those that 
did not have labels under the HUGO plan, and (5) only confirmed 
 disease-causing genetic variants would be included in the list (i.e., patho-
genic variants in a gene need to be reported by at least two independent 
groups). The newly proposed nomenclature system solves several of  the 
problems with the HUGO nomenclature system. However, as further 
described below, the new system also creates new problems.27
Permitting multiple prefixes and establishing new prefixes as pro-
posed by the MDS task force address the problem of  forcing complex 
phenotypes into HUGO’s oversimplified single prefix plan. For exam-
ple, pure dystonia is designated with DYT only, while dystonia com-
bined with parkinsonism would be designated as DYT/PARK, and 
dystonia combined with ataxia would be designated as DYT/SCA. New 
prefixes would include tremor (TREM), paroxysmal dyskinesias (PxD), 
myoclonus (MYOC), and others. The MDS task force further recom-
mended that phenotypic prefixes should be assigned only when the phe-
notype is observed as a prominent feature in the majority of  cases and 
should be confirmed by at least two independent groups. Together, 
these changes would more accurately reflect the phenotype, including 
mixed phenotypes, and even changing phenotypes resulting from the 
growth of  knowledge as new cases are described.
A major challenge in implementing the proposed changes is that 
assigning prefixes requires some arbitrary decisions. For example, the 
MDS task force recommended that DYT11 (SGCE) should be labeled as 
DYT-SGCE. However, myoclonus is often a more prominent aspect of  
the phenotype than dystonia.2,3 Hence, it could be argued that the 
proper prefix should be MYOC, or MYOC/DYT. The task force also 
recommended that DYT1 should be labeled as DYT-TOR1A to empha-
size the importance of  dystonia. However, the majority of  dystonia 
patients also have tremor, which can sometimes be the most prominent 
feature. Here again, it could be argued that a more accurate prefix 
would be DYT/TREM-TOR1A. These examples highlight the arbi-
trary nature of  prefix assignment under the proposed system and raise 
an even more difficult question regarding who has the authority to 
declare the most prominent phenotype(s), and who will arbitrate when 
there are disagreements among experts. Furthermore, the label will 
change when alternative phenotypes are discovered, a phenomenon 
that is nearly universal in human genetics.
Lesch–Nyhan disease provides another example. The MDS task 
force recommended that this disease should be designated as DYT/
CHOR-HPRT1. However, chorea is not a prominent feature in the 
majority of  either classic9 or atypical variant phenotypes10 associated 
with pathogenic genetic variants in HPRT1. The reasons for including 
CHOR therefore could be disputed, and a somewhat arbitrary deci-
sion would have to be made. Who arbitrates the disagreement? On the 
other hand, there are some other very important aspects of  the pheno-
type that are nearly universal, such as intellectual disability, overpro-
duction of  uric acid, and macrocytic erythrocytes.28 Should all of  these 
phenotypic elements be acknowledged too? If  the answer is “no,” then 
the proposed nomenclature system is relevant only for the movement 
disorder, and it is not likely to be adopted by colleagues in genetics 
outside of  the movement disorders field. If  the answer is “yes,” then it 
is easy to see how the proposed nomenclature system rapidly becomes 
unwieldy for complex phenotypes.
Under the new plan, a DYT label would be assigned for all genes 
associated with dystonia, including those that never had a DYT name 
before. This proposal means that genes discovered before the HUGO 
system started would be recognized. It also means that new genes that 
bypassed the need to name a locus would be recognized. This proposal 
corrects the weakness of  the traditional nomenclature plan that led to 
lists neglecting a large number of  genes associated with dystonia. 
Aside from providing a system to catalog dystonia-related genes, this 
plan has limited value. For example, under the new system, Wilson’s 
disease is caused by pathogenic variants in the ATP7B gene and might 
be assigned DYT/PARK/TREM-ATP7B. It seems very unlikely that 
clinicians or geneticists will adopt this designation over “Wilson’s dis-
ease” or the “ATP7B” gene. If  this is the case, the value of  the new 
label is limited.
Also under the new plan, the DYT number would be replaced by the 
actual gene. DYT1 in HUGO nomenclature system is replaced by 
DYT-TOR1A in the MDS task force nomenclature system. Similarly, 
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DYT5 (dopa-responsive dystonia) becomes DYT/PARK-GCH1 or 
DYT/PARK-TH to acknowledge the frequent occurrence of  parkin-
sonism in this disorder, as well as potentially different causal genes. This 
proposal means that a name cannot be assigned until a gene is identi-
fied, preventing confusion associated with incorrect assignment of  loci 
names that occurred with the old nomenclature system. However, the 
requirement for gene identification defeats the original purpose of  this 
nomenclature system: to aid the identification of  families with similar 
phenotypes to find these genes in the first place. This limitation would 
require a new nomenclature plan to identify families in which a sus-
pected gene needs to be confirmed.
Synopsis
In summary, the HUGO-based locus naming system is fraught with 
problems. The new nomenclature system proposed by the MDS task 
force solves some of  these problems but creates new ones. The new 
plan reduces the likelihood of  inappropriate or incomplete phenotypic 
 prefixes, intends to be more inclusive and complete, and limits errors in 
the numbering system. At the same time, the new system brings limita-
tions of  arbitrary phenotypic prefixes, complex and unwieldly names, 
and a loss of  the original value of  naming potential novel loci for linkage 
studies. The nomenclature system proposed by the MDS task force also 
requires a high degree of  expertise in neurogenetics, and it is still under 
development, because many disorders have not yet been given names. 
Even if  all relevant disorders can be given labels, these labels will 
continue to evolve as new phenotypes and potential new disease-associ-
ated genes are described. This means that the proposed nomenclature 
will be constantly changing. Without stable names, it is likely that this 
system will be difficult to learn and will contribute to ongoing 
confusion.
The fundamental problem is that both gene nomenclature systems 
are trying to be something they are not. The original purpose was to 
identify families with similar phenotypes to aid linkage studies (Table 1). 
Although HUGO intended that the DYT labels should be dropped once 
the responsible gene was found, the labels were adopted for naming dis-
orders and cataloging them. A relatively simple goal therefore has been 
distorted into a tool for organizing genetic disorders. The distortion of  
the original intent has produced many unintended consequences. For 
example, the HUGO-based DYT list has been reproduced numerous 
times in reviews on dystonia and referred to as a classification system for 
genetics. This convention is not a classification system, rather it is a list.
Another unintended consequence is that the DYT labels are now 
being translated for other uses as if  they are abbreviations. There are 
now multiple published articles in the literature with “Dystonia-1” in 
the title line rather than the more commonly accepted name of  “DYT1 
dystonia.”29,30 The same is true for DYT6 dystonia and “Dystonia-6.”31,32 
The International Classification of  Diseases and Related Health 
Problems medical classification system of  the World Health 
Organization has similarly translated these DYT labels as if  they are 
abbreviations, and terms such as “Dystonia-1” and “Dystonia-6” are 
Table 1.  Comparison of  Traditional and New Nomenclature Plans
Characteristic Traditional HUGO Plan MDS Task Force Plan
Useful for linkage studies Yes No; it requires identification of  gene 
before a label is assigned
Inclusive of  all dystonias Poor; large numbers of  dystonias are 
missing and will never be added
Modest; large numbers of  dystonias are 
still not assigned labels
Identifies a single unique disorder No Yes
Label is stable over time Yes; except for errors No, prefix will evolve as new 
information expands the phenotype
Clear process for assigning labels Yes; assigned by HUGO No; unclear authority for assignment
Simple and easy to use Yes No; requires substantial expertise in 
neurogenetics
Accommodates multiple movement phenotypes No Yes
Accommodates non-movement phenotypes No No
Likely to be adopted by non-movement fields Yes; already in use across all of  medicine No; relevant only for movement field
Accurately reflects the dominant movement 
disorder phenotype
No; not all DYT labels correspond to 
disorders where dystonia is the dominant 
feature
Partly; based on order of  prefix listing
Useful clinical system for classifying dystonias 
into meaningful groups
No; this is a list, not a classification system Partly; depending on prefix
Useful biological system for classifying dystonias 
into meaningful groups
No; this is a list, not a classification system No; provides gene name only
Abbreviations: HUGO, the Human Genome Organization; MDS, Movement Disorders Society.
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now being used to identify diagnoses for clinical billing and insurance 
coverage. The proliferation of  multiple names for a single disorder is 
not useful.
Finally, it should be noted that neither the traditional nor the more 
recently proposed nomenclature strategies are compatible with oligo- 
inheritance, where one disorder may be the result of  combined 
defects in multiple genes. None of  the proposed nomenclature plans 
strategies is compatible with disorders associated with genomic dele-
tions, which may span several genes.
Recommendations for the future
For clinical neurologists, memorizing the HUGO-based DYT num-
bers is not useful because there is limited practical value in a label that 
estimates a chromosomal locus (e.g., DYT24). Similarly, using labels 
that attempt to provide a synopsis of  the phenotype as a prefix to the 
gene (e.g., DYT/PARK-ATP1A3) presents an oversimplified view for 
many disease phenotypes, and it is a cumbersome task to learn and 
apply. These nomenclature systems are not appropriate for application 
in the clinic.
For clinical neurologists, genetic disorders can be described by the 
name of  the syndrome or disease (e.g., Wilson’s disease) and/or the 
responsible gene (e.g., ATP7B). An additional label is not needed. 
In fact, this approach has been adopted already for several genetic 
 disorders. For example, the many varied phenotypes associated with 
pathogenic variants in GLUT1 have been called “GLUT1 deficiency 
syndromes.”33 If  a clinician wants to refer to a more specific phenotype, 
then wordings such as “GLUT1-associated paroxysmal dyskinesia” can 
be used. Similarly, the many phenotypes associated with pathogenic 
variants in ATP1A3 have collectively been called “ATP1A3-related dis-
orders.”8 For this approach to nomenclature, there is no need or value 
in an additional “DYT” label.
For basic scientists interested in the genetics of  dystonia or its biolog-
ical pathways, the HUGO-based list is limited because it is largely 
incomplete and has numerous errors. The new system provided by the 
MDS task force also bears several limitations because it is still incom-
plete, it relies on arbitrary decisions by individuals with uncertain 
authority to define the most relevant phenotypes, and it will always be in 
flux and lagging behind knowledge created by constant identification of  
novel disease-associated genes and gene-related phenotypes. 
Furthermore, the pathway for arbitrating disagreements for labels is not 
clear; therefore, this approach will inevitably lead to experts using differ-
ent labels for the same disorder.
The recognition that multiple dystonia-associated genes are part of  
independent but convergent biological pathways is one of  the most 
important conceptual advances made possible by the remarkable growth 
in the number of  relevant genes.34,35 In the near future, classifying genes 
based on patterns of  inheritance or shared biological pathways will have 
more relevance for understanding their biology and directing treatment 
strategies than classifying them according to varied and changing clini-
cal phenotypes. Such classification systems may serve to better identify 
individuals with different genotypes who may respond to similar mech-
anism-based treatments.
New disorders and new genes are being found regularly. Of  course, 
when they are first described, those describing them will have to recom-
mend appropriate names. These recommendations should not be 
bound by complex nomenclature plans that have limited clinical or sci-
entific value.
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